USMLE Step 2 CK practice question: Mild asthma (GINA Track 1): as-needed low-dose budesonide-formoterol reliever
USMLE Step 2 CKRespiratoryInternal Medicine
According to current GINA recommendations, which of the following is the most appropriate treatment?
- Continue as-needed albuterol alone
- Daily montelukast with as-needed albuterol
- Daily salmeterol with as-needed albuterol
- As-needed low-dose budesonide-formoterol
- Daily medium-dose fluticasone-salmeterol with as-needed albuterol
Show answer and explanation
Correct answer: D. As-needed low-dose budesonide-formoterol
This patient has mild asthma (symptoms several times a week but on fewer than 4 to 5 days a week, rare night waking, no exacerbations) treated with a short-acting beta2-agonist (SABA) alone. GINA no longer recommends SABA-only treatment for adults or adolescents: even mild asthma involves airway inflammation, and SABA monotherapy is associated with severe exacerbations and asthma death. In GINA's preferred Track 1, steps 1 and 2 use low-dose inhaled glucocorticoid (ICS)-formoterol taken as needed for symptom relief, called an anti-inflammatory reliever. Each inhalation delivers an ICS together with formoterol, a long-acting beta2-agonist with rapid onset, so anti-inflammatory treatment rises exactly when symptoms rise. Compared with a SABA alone, this approach reduces severe exacerbations by more than half; compared with daily low-dose ICS plus a SABA, it gives similar protection with much less total steroid exposure.
If asthma remains uncontrolled, Track 1 escalates to maintenance-and-reliever therapy (MART) with ICS-formoterol, low dose at step 3 and medium dose at step 4. Track 2, the alternative, pairs a SABA reliever with a daily ICS or with an ICS taken whenever the SABA is used. LABA monotherapy without an ICS is never appropriate in asthma.
Why the other options are wrong
- A. Continue as-needed albuterol alone — SABA-only treatment is no longer recommended for adults or adolescents because it increases the risk of severe exacerbations and asthma death.
- B. Daily montelukast with as-needed albuterol — Leukotriene receptor antagonists are less effective than ICS and carry a boxed warning for neuropsychiatric effects; they are not preferred.
- C. Daily salmeterol with as-needed albuterol — LABA monotherapy without an ICS increases the risk of severe exacerbations and asthma-related death.
- E. Daily medium-dose fluticasone-salmeterol with as-needed albuterol — Daily medium-dose ICS-LABA is step 4 therapy and is excessive for mild asthma.
Key point
For mild asthma in adults and adolescents, GINA's preferred treatment is as-needed low-dose ICS-formoterol rather than a SABA alone.
Memory hook
In GINA, the reliever must also fight inflammation: every puff of budesonide-formoterol brings a steroid along. No SABA solo.
15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.
Play free